Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy.
Imai
Kazuhiro
K
Department of Orthopaedic Surgery, Tokyo Metropolitan Geriatric Medical Center, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan. imaik-ort@umin.ac.jp
Yamamoto
Seizo
S
Anamizu
Yorito
Y
Horiuchi
Toshiyuki
T
D000368:Aged; D019386:Alendronate / Q000009:adverse effects* / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects* / Q000293:injuries; D005260:Female; D006620:Hip Fractures / Q000139:chemically induced*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy; D012307:Risk Factors
D019386:Alendronate
Bone. 1996 Feb;18(2):141-50
8833208
J Bone Miner Res. 2000 Apr;15(4):613-20
10780852
Osteoporos Int. 1999;9(5):461-8
10550467
Philos Trans R Soc Lond B Biol Sci. 1984 Feb 13;304(1121):509-18
6142490
N Engl J Med. 1995 Nov 30;333(22):1437-43
7477143
Am J Med. 1996 Nov;101(5):488-501
8948272
AJR Am J Roentgenol. 1985 Feb;144(2):337-41
3871281
J Bone Miner Metab. 2004;22(6):618-25
15490274
J Clin Endocrinol Metab. 2005 Mar;90(3):1897-9
15758064
Curr Opin Nephrol Hypertens. 2003 Jul;12(4):387-403
12815335
AJR Am J Roentgenol. 1985 Sep;145(3):601-6
3875262
Bone. 2001 May;28(5):524-31
11344052
J Bone Miner Res. 1988 Apr;3(2):133-44
3213608
Radiology. 1983 Mar;146(3):783-5
6828693
J Clin Endocrinol Metab. 2005 Mar;90(3):1294-301
15598694
Lancet. 1996 Dec 7;348(9041):1535-41
8950879
JAMA. 1998 Dec 23-30;280(24):2077-82
9875874
N Engl J Med. 2004 Mar 18;350(12 ):1189-99
15028823
J Clin Endocrinol Metab. 2001 Apr;86(4):1835-6
11297626
Arch Intern Med. 1997 Dec 8-22;157(22):2617-24
9531231
J Bone Miner Res. 2004 Aug;19(8):1259-69
15231012